Pediatrics - Acetaminophen (Paracetamol) Poisoning

Pediatrics - Acetaminophen (Paracetamol) Poisoning

Basics

Description

Acetaminophen, also known as paracetamol, poisoning occurs when excessive quantities of the medication are ingested either as a single acute overdose or through repeated administration of doses exceeding the recommended therapeutic range.

Paracetamol is widely available under numerous brand names and is frequently included in combination medications used to treat pain, fever, colds, and other common illnesses.

Paracetamol poisoning may initially produce few or no clinical symptoms. Significant hepatic or renal injury can develop before obvious manifestations become apparent, making early recognition and appropriate investigation essential.

Following a single acute overdose, the risk of hepatotoxicity is assessed using the serum paracetamol concentration plotted against the time since ingestion on the Rumack-Matthew nomogram.

A concentration at or above the appropriate treatment line indicates the need for antidotal treatment with N-acetylcysteine.

Serious hepatotoxicity following a single accidental exploratory ingestion is uncommon in young children compared with intentional overdoses among adolescents.

In toddlers, significant paracetamol-associated liver injury is more frequently associated with repeated supratherapeutic dosing, often resulting from medication administration errors.

Epidemiology

Analgesic medications are among the most frequently implicated pharmaceutical agents in poisoning exposures reported to poison control centers in the United States.

Historically, paracetamol-containing products have accounted for approximately 45% of analgesic poisoning exposures reported to these centers.

Paracetamol toxicity is a major cause of drug-induced liver injury and is recognized as the leading cause of acute liver failure in the United States.

Poisoning may occur unintentionally when caregivers administer excessive doses to children with fever or pain, or intentionally through self-poisoning, particularly among adolescents.

The widespread availability of paracetamol, including its presence in combination preparations, contributes to the risk of inadvertent overdose.

Risk Factors

Several clinical and behavioral factors may increase the likelihood of paracetamol overdose or influence the severity of toxicity.

Depression And Psychological Disorders

Depression and other psychological difficulties may increase the risk of intentional self-poisoning, particularly among adolescents.

A comprehensive psychosocial assessment is important when an intentional overdose is suspected.

Chronic Pain Syndromes

Children and adolescents with persistent pain conditions may be exposed to frequent or prolonged paracetamol use.

Repeated dosing, particularly when multiple paracetamol-containing medications are used simultaneously, may increase the risk of unintentional toxicity.

Glutathione Depletion

Glutathione is essential for detoxifying the toxic metabolite of paracetamol.

Conditions associated with reduced glutathione availability may increase susceptibility to liver injury.

Examples include prolonged fasting, persistent vomiting, malnutrition, and chronic excessive alcohol consumption.

Hepatic Enzyme Induction

Certain medications and substances may alter the activity of hepatic enzymes involved in paracetamol metabolism.

Chronic alcohol exposure and medications such as isoniazid have historically been associated with changes in CYP2E1 activity.

Their effects on clinical toxicity are complex and should be considered alongside nutritional status, dosing history, and underlying liver disease rather than interpreted as independent predictors of hepatotoxicity.

General Prevention

Prevention of paracetamol poisoning requires safe medication storage, correct dosing practices, and awareness of combination pharmaceutical preparations.

Safe Medication Storage

Paracetamol-containing medications should be stored in containers with child-resistant closures.

All medications should be kept out of sight and reach of young children, preferably in a locked storage area.

Caregivers should avoid leaving medications unattended or transferring them into unlabeled containers.

Appropriate Medication Administration

Parents and caregivers should receive clear instructions regarding the correct paracetamol dose, dosing interval, and maximum recommended daily amount.

Pediatric dosing should be based on the child’s weight and the concentration of the specific preparation.

An appropriate oral syringe or calibrated medication-measuring device should be used for liquid formulations.

Household teaspoons should not be used because they may result in inaccurate dosing.

Avoidance Of Duplicate Medication Exposure

Caregivers should be informed that paracetamol may be present in multiple products, including combination cold and flu medications.

Using two or more paracetamol-containing products simultaneously may result in an unintended overdose.

Medication labels should be checked carefully before administration.

Pathophysiology

Paracetamol toxicity primarily results from the excessive formation and accumulation of a reactive metabolite that damages hepatocytes.

Under normal circumstances, most absorbed paracetamol undergoes metabolism in the liver through glucuronidation and sulfation.

These pathways produce relatively nontoxic conjugated metabolites that can be eliminated through the kidneys.

A smaller proportion of paracetamol undergoes oxidation through the hepatic cytochrome P450 enzyme system, particularly CYP2E1.

This process generates the highly reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI).

Normal Detoxification

Under therapeutic conditions, NAPQI is rapidly neutralized by conjugation with glutathione.

The resulting nontoxic compounds are subsequently eliminated from the body.

Because glutathione availability is generally sufficient at recommended doses, significant tissue injury does not occur.

Toxic Metabolite Accumulation

Following overdose, the major glucuronidation and sulfation pathways become relatively saturated.

A greater proportion of paracetamol is subsequently metabolized through pathways that produce NAPQI.

As NAPQI production increases, hepatic glutathione stores may become depleted.

When the available glutathione is insufficient to neutralize NAPQI, the reactive metabolite binds to cellular proteins and causes oxidative stress and mitochondrial dysfunction.

Consequences Of Overdose

Several important changes may occur following a toxic ingestion.

Prolonged Drug Elimination: The elimination half-life of paracetamol may become prolonged as metabolic pathways are overwhelmed or hepatic function deteriorates.

Increased NAPQI Formation: A larger amount of the toxic metabolite is produced.

Glutathione Depletion: The supply of glutathione becomes insufficient to meet the increased demand for detoxification.

Hepatocellular Injury: Accumulation of NAPQI produces hepatocyte damage, particularly in the centrilobular region of the liver.

Renal Toxicity: Acute kidney injury may occur in severe poisoning, occasionally even without extensive hepatic injury.

In severe cases, progressive hepatocellular destruction may lead to acute liver failure, coagulopathy, metabolic acidosis, encephalopathy, and multiorgan dysfunction.

Etiology

Paracetamol poisoning may result from a single acute ingestion or repeated administration of excessive doses.

The amount ingested, duration of exposure, time elapsed before treatment, and presence of other clinical risk factors influence the likelihood of toxicity.

Single Acute Overdose

A single acute ingestion of approximately 200 mg/kg or 10 g, whichever is lower, warrants urgent toxicological assessment.

These quantities are commonly used as referral thresholds rather than absolute boundaries between safe and toxic exposures.

Some patients may require treatment following smaller doses, particularly when the history is unreliable or other concerning findings are present.

The serum paracetamol concentration and time since ingestion are essential for determining the need for antidotal therapy when the Rumack-Matthew nomogram is applicable.

Repeated Supratherapeutic Ingestion

Repeated supratherapeutic ingestion occurs when excessive paracetamol doses are taken over an extended period, rather than during one acute ingestion episode.

Important exposure thresholds that warrant assessment include:

• Within 24 Hours: Approximately 200 mg/kg or 10 g, whichever is lower.
• Within 48 Hours: Approximately 150 mg/kg per 24 hours or 6 g daily, whichever is lower.
• For More Than 48 Hours: Approximately 100 mg/kg per 24 hours or 4 g daily, whichever is lower.

These thresholds help identify patients who require medical evaluation. They do not establish hepatotoxicity by themselves.

Children with symptoms, suspected liver injury, or potentially excessive dosing may require assessment even when the reported amount is below these thresholds.

Factors Increasing Susceptibility

Patients with prolonged vomiting, malnutrition, or reduced glutathione availability may be more susceptible to liver injury from repeated excessive dosing.

The clinical significance of the exposure should therefore be assessed using both the medication history and the patient’s overall condition.

Commonly Associated Conditions

Paracetamol is frequently included in combination pharmaceutical preparations.

These products may contain antihistamines, decongestants, cough suppressants, opioids, or other analgesics.

An overdose involving a combination product may therefore cause toxicity related to more than one active ingredient.

Adolescents who intentionally ingest excessive medication frequently take multiple pharmaceutical preparations.

Coingested medications may produce additional clinical manifestations, delay paracetamol absorption, or complicate interpretation of the clinical presentation.

A comprehensive assessment should identify all possible substances involved in the exposure.

Diagnosis

Early diagnosis is essential because significant paracetamol poisoning may remain clinically silent during the initial stages.

The evaluation should establish the amount ingested, timing of exposure, type of formulation, presence of coingestants, and likelihood of hepatic injury.

The principal diagnostic investigations are serum paracetamol concentration and biochemical assessment of hepatic function.

The Rumack-Matthew nomogram is used when the ingestion pattern and timing meet the criteria for its application.

History

A detailed medication history is the foundation of evaluating suspected paracetamol poisoning.

The reliability of the reported dose and timing should be carefully assessed because inaccurate information may lead to inappropriate risk estimation.

History Of Pain Or Fever

Paracetamol exposure should be considered in any child receiving medication for pain or fever.

Caregivers should be asked about all medications administered, including prescription drugs, over-the-counter preparations, and combination cold remedies.

The name, concentration, amount, frequency, and duration of each medication should be documented.

Amount Of Paracetamol Ingested

The clinician should estimate the total amount of paracetamol ingested in milligrams and calculate the dose relative to body weight.

The total dose should include paracetamol contained in combination preparations.

A single reported acute ingestion below approximately 200 mg/kg or 10 g is generally less likely to cause significant toxicity in an otherwise healthy individual, but dose history alone should not determine whether further evaluation is necessary.

The possibility of an inaccurate history, repeated dosing, delayed absorption, or associated clinical symptoms should also be considered.

Timing Of Ingestion

Determining the time of ingestion is particularly important because it allows the serum paracetamol concentration to be interpreted using the Rumack-Matthew nomogram.

The clinician should establish the earliest and latest possible ingestion times when the exact timing is uncertain.

When the timing cannot be determined reliably, the nomogram should not be used to rule out toxicity.

Extended-Release Preparations

Paracetamol is available in immediate-release and modified-release formulations.

Extended-release products may undergo delayed or prolonged gastrointestinal absorption.

This may complicate interpretation of a single serum paracetamol concentration and require additional measurements.

Medication History

A complete medication history should identify substances that may affect hepatic metabolism or contribute to additional toxicity.

Particular attention should be given to combination analgesics, isoniazid, and other potentially hepatotoxic medications.

Clinical Symptoms

Early paracetamol poisoning may be asymptomatic.

When symptoms occur, they may include nausea, vomiting, anorexia, and nonspecific abdominal discomfort.

The absence of symptoms during the initial hours following ingestion does not exclude potentially serious poisoning.

Intentional Ingestion

In adolescents, the clinician should assess whether the overdose was accidental or intentional.

When deliberate self-poisoning is suspected, evaluation should include possible coingestants and an appropriate mental health and safety assessment.

Physical Examination

The physical examination may be normal during the early stages of paracetamol poisoning, even after a potentially hepatotoxic ingestion.

Clinical findings become more apparent as hepatic injury develops.

General Appearance

The child may initially appear well or exhibit only nonspecific symptoms such as nausea, vomiting, or fatigue.

In more severe poisoning, signs of dehydration, altered mental status, poor perfusion, or systemic deterioration may become evident.

Right Upper Quadrant Tenderness

Tenderness over the right upper quadrant of the abdomen may indicate paracetamol-induced hepatitis.

This finding is more likely to occur after hepatic injury has developed rather than immediately following ingestion.

Signs Of Hepatic Dysfunction

Progressive liver injury may produce jaundice, hepatomegaly, hypoglycemia, and bleeding manifestations associated with impaired coagulation factor synthesis.

Signs Of Severe Poisoning

Advanced toxicity may be associated with encephalopathy, metabolic acidosis, hypotension, acute kidney injury, and multiorgan dysfunction.

These findings require immediate critical care assessment.

Differential Diagnosis

Other conditions associated with acute liver injury should be considered when evaluating patients with suspected paracetamol toxicity.

Infectious Hepatitis

Viral and other infectious forms of hepatitis may produce elevated hepatic transaminases, nausea, vomiting, jaundice, and right upper quadrant discomfort.

The clinical history, infectious exposures, and appropriate laboratory investigations may help distinguish infectious hepatitis from drug-induced hepatotoxicity.

Other Drug-Induced Hepatitis

Several prescription medications, over-the-counter products, and herbal preparations may cause acute hepatic injury.

A complete medication and substance exposure history is therefore essential.

Other potential causes of acute liver injury should also be considered when the clinical presentation or laboratory findings are inconsistent with the reported paracetamol exposure.

Diagnostic Tests And Interpretation

Laboratory evaluation is essential because symptoms alone cannot reliably identify children at risk of paracetamol-induced liver injury.

Initial investigations should assess the serum paracetamol concentration, evidence of hepatocellular injury, hepatic synthetic function, renal function, and metabolic disturbances.

Additional testing may be necessary when multiple medications have been ingested.

Initial Laboratory Investigations

Serum Paracetamol Concentration

Measurement of the serum paracetamol concentration is the principal investigation used to assess toxicity following an acute ingestion.

For a single acute ingestion with a reliably established time, the concentration is plotted against the time elapsed since ingestion on the Rumack-Matthew nomogram.

The result determines whether treatment with N-acetylcysteine is indicated.

Timing Of Serum Sampling

A serum paracetamol concentration obtained before four hours after acute ingestion cannot reliably be used to exclude toxicity by nomogram interpretation.

For an immediate-release preparation, a sample collected at four hours or later can generally be interpreted using the nomogram, provided the history is reliable and the ingestion occurred within the applicable time window.

If the child presents more than four hours after ingestion, the serum concentration should be obtained promptly.

When ingestion involves an extended-release formulation or substances that delay gastric emptying, repeat serum measurements may be necessary.

Rumack-Matthew Nomogram

The Rumack-Matthew nomogram estimates the risk of hepatotoxicity by relating the serum paracetamol concentration to the time since acute ingestion.

The commonly used treatment line begins at a concentration of 150 micrograms/mL at four hours after ingestion and declines over time.

N-acetylcysteine should be initiated when the serum paracetamol concentration is on or above the treatment line.

The nomogram is intended for an acute ingestion with a reasonably established time, generally when a serum level is obtained between four and 24 hours after ingestion.

It should not be used to assess repeated supratherapeutic ingestion or to exclude toxicity when the time of ingestion is unknown.

Hepatic Transaminases

Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are important markers of paracetamol-induced hepatocellular injury.

AST and ALT concentrations may begin to increase approximately 12–24 hours after a significant overdose, although the timing varies.

Marked elevations suggest substantial hepatocellular injury.

Serial measurements are useful for monitoring disease progression and response to treatment.

Liver Function And Coagulation Studies

As hepatic transaminase concentrations increase, additional investigations are necessary to evaluate liver function and identify complications.

Important tests include:

• Prothrombin time (PT).
• International normalized ratio (INR).
• Activated partial thromboplastin time (aPTT).
• Serum glucose.
• Serum albumin.
• Serum bilirubin.

Prolongation of coagulation times may indicate impaired hepatic synthesis of coagulation factors.

However, mild PT or INR abnormalities may occasionally result from effects of paracetamol exposure or N-acetylcysteine therapy without severe hepatocellular damage.

These results should therefore be interpreted alongside transaminase concentrations and the overall clinical condition.

Renal Function

Serum creatinine and other renal function investigations should be monitored when significant toxicity is suspected.

Acute kidney injury may occur as a complication of severe paracetamol poisoning.

Acid-Base Status

Blood gas analysis and assessment of plasma pH may be necessary in patients with severe poisoning.

Metabolic acidosis may indicate serious systemic toxicity, mitochondrial dysfunction, or advanced hepatic failure.

Interpretation Of Declining Transaminase Concentrations

A reduction in previously elevated AST or ALT levels may indicate recovery of hepatocellular function.

However, falling transaminase concentrations may also occur in advanced hepatic failure when extensive hepatocyte destruction has occurred.

Therefore, a declining AST concentration should not be interpreted as evidence of improvement without considering INR, glucose, lactate, mental status, and other measures of organ function.

Serum Salicylate Concentration

A serum salicylate concentration should be considered when an analgesic overdose may involve aspirin or another salicylate-containing preparation.

This is especially important in intentional or uncertain multidrug ingestions.

Pathological Findings

Centrilobular Hepatic Necrosis

The characteristic pathological lesion associated with severe paracetamol toxicity is hepatic zone III necrosis, also known as centrilobular necrosis.

This pattern primarily affects hepatocytes surrounding the central veins of hepatic lobules.

The centrilobular region is particularly vulnerable because of its relatively high activity of enzymes involved in NAPQI formation and its susceptibility to oxidative injury.

In severe poisoning, extensive hepatocellular necrosis may progress to acute liver failure.

Treatment

General Measures

Management of paracetamol poisoning should begin with rapid assessment of the child’s clinical condition and identification of potentially dangerous coingestants.

The goals of treatment are to reduce further drug absorption when appropriate, prevent hepatic injury, recognize complications, and provide antidotal therapy without unnecessary delay.

N-acetylcysteine is the specific antidote for paracetamol poisoning.

Its effectiveness is greatest when administered early, but treatment may still be beneficial in patients presenting after liver injury has developed.

Treatment should follow an established institutional poisoning protocol, with clinical toxicology or poison center consultation when indicated.

Initial Emergency Management

Assessment Of Multiple Drug Ingestion

All patients with suspected paracetamol overdose should be evaluated for possible exposure to additional medications or toxic substances.

Combination pharmaceutical preparations and intentional multidrug ingestions may cause clinical manifestations unrelated to paracetamol itself.

The clinician should assess airway protection, breathing, circulation, mental status, and evidence of additional toxicological syndromes.

Stabilization

Children with significant vomiting, dehydration, hypotension, altered mental status, or suspected hepatic failure may require intravenous fluids, correction of metabolic abnormalities, and supportive care.

Airway protection and cardiorespiratory monitoring may be necessary in severe cases.

Gastrointestinal Decontamination

Activated charcoal may be considered in selected patients presenting soon after a potentially toxic ingestion.

Its use depends on the estimated dose, time since ingestion, formulation, clinical stability, and ability to protect the airway.

Medication

First-Line Treatment

N-acetylcysteine is the preferred antidotal treatment for clinically significant paracetamol poisoning.

It acts primarily by restoring glutathione availability, allowing detoxification of NAPQI and reducing further hepatocellular injury.

Treatment may be administered intravenously or orally according to the clinical circumstances and available protocols.

Single Acute Overdose

Activated Charcoal

Activated charcoal may reduce gastrointestinal absorption when administered shortly after a potentially hepatotoxic ingestion.

It is generally most useful within approximately one hour after ingestion, although administration later may be considered in selected circumstances, including large overdoses or preparations associated with delayed absorption.

A commonly used pediatric dose is approximately 1 g/kg, subject to institutional maximum doses and toxicology guidance.

Activated charcoal should not be administered when the patient cannot adequately protect the airway unless appropriate airway protection has been established.

Indications For N-Acetylcysteine

N-acetylcysteine should be administered when the serum paracetamol concentration, measured at an appropriate time following acute ingestion, falls on or above the treatment line of the Rumack-Matthew nomogram.

Treatment is also indicated in selected patients with suspected paracetamol-induced liver injury, including those presenting late or with an unknown time of ingestion.

Delayed Presentation

When a potentially toxic ingestion is strongly suspected and waiting for the serum paracetamol result would delay antidotal treatment beyond eight hours after ingestion, N-acetylcysteine should be started while laboratory results are pending.

Early administration is important because the protective effect of N-acetylcysteine is greatest before substantial hepatic injury develops.

Intravenous N-Acetylcysteine

Intravenous N-acetylcysteine is commonly used when antidotal treatment is indicated, particularly in patients with significant vomiting, impaired consciousness, or severe poisoning.

Several intravenous treatment protocols are available.

Standard Three-Infusion Protocol

One established regimen administers a total of 300 mg/kg over 21 hours.

First Infusion: Loading Dose

Administer 150 mg/kg intravenously over one hour.

For dosing protocols capped at 100 kg, the maximum loading dose is 15 g.

Second Infusion

Administer 50 mg/kg intravenously over four hours.

This is equivalent to an infusion rate of 12.5 mg/kg/hour, with a maximum dose of 5 g when the 100-kg dosing cap applies.

Third Infusion

Administer 100 mg/kg intravenously over 16 hours.

This corresponds to an infusion rate of 6.25 mg/kg/hour, with a maximum dose of 10 g when the 100-kg dosing cap applies.

The total initial dose is 300 mg/kg over 21 hours.

Alternative Intravenous Regimens

Some institutions use simplified two-infusion protocols that deliver the same total dose over approximately 20 hours.

These regimens may reduce certain infusion-related adverse reactions.

The prescribed formulation, dilution volume, and infusion schedule should follow the local pediatric protocol, especially in younger children where inappropriate fluid volumes may cause complications.

The initial infusion schedule does not automatically determine the total treatment duration. N-acetylcysteine may need to be continued if biochemical or clinical evidence of toxicity persists.

High-Risk Paracetamol Overdose

Very large paracetamol ingestions may require modified treatment strategies.

High-risk exposure includes an acute ingestion of approximately 30 g or more, or a serum paracetamol concentration above the high-risk line on the revised Rumack-Matthew nomogram.

The high-risk nomogram line begins at approximately 300 micrograms/mL at four hours after ingestion.

Patients with extremely elevated paracetamol concentrations may develop early metabolic acidosis, elevated lactate, altered consciousness, or other manifestations of mitochondrial dysfunction.

Specialist Consultation

Urgent clinical toxicology consultation is recommended for very large overdoses, particularly when serum concentrations exceed approximately 400 micrograms/mL or clinical evidence suggests mitochondrial dysfunction.

Higher N-acetylcysteine doses or additional treatments may be considered by specialists.

The optimal intensified regimen varies according to the exposure and clinical findings.

Standard antidotal therapy should not be delayed while arranging specialist advice.

Oral N-Acetylcysteine

Oral N-acetylcysteine is an alternative when intravenous treatment is not necessary or appropriate.

Oral Loading Dose

The traditional oral regimen begins with a loading dose of 140 mg/kg.

Oral Maintenance Doses

Following the loading dose, 70 mg/kg is administered every four hours.

The conventional regimen consists of 17 maintenance doses, giving a total scheduled duration of approximately 72 hours.

The precise dose limits and the duration of treatment should follow the applicable prescribing protocol and the child’s laboratory response.

Practical Administration Considerations

Oral N-acetylcysteine has a strong sulfur-like odor and unpleasant taste that may cause nausea or vomiting.

Chilling the solution and mixing it with a suitable flavored drink may improve tolerance.

Antiemetic treatment may be necessary when vomiting interferes with administration.

In selected patients, administration through a nasogastric tube may be considered when oral ingestion is difficult.

Repeated Supratherapeutic Ingestion

Repeated administration of excessive paracetamol doses requires a different approach from the evaluation of a single acute overdose.

The Rumack-Matthew nomogram should not be used to determine treatment in patients with repeated supratherapeutic ingestion extending beyond 24 hours.

Assessment should instead consider the cumulative dosing history, serum paracetamol concentration, hepatic transaminase levels, symptoms, and underlying clinical risk factors.

Indications For N-Acetylcysteine

N-acetylcysteine should be considered when a child has a history of repeated excessive paracetamol administration and laboratory or clinical findings indicate possible toxicity.

Important indications include:

• Repeated doses exceeding approximately 150 mg/kg per 24 hours or 6 g daily over consecutive days.
• Symptoms suggesting paracetamol toxicity, including persistent vomiting, anorexia, or abdominal pain.
• Elevated AST or ALT concentrations.
• A serum paracetamol concentration greater than 20 micrograms/mL.
• Evidence of hepatic dysfunction or an unexpectedly elevated serum paracetamol concentration relative to the reported dosing history.

Treatment is generally recommended when the serum concentration exceeds 20 micrograms/mL or hepatic transaminases are abnormal in the setting of repeated supratherapeutic ingestion.

Specialist toxicology consultation is recommended because the risk assessment and treatment requirements differ from acute overdose management.

Duration Of N-Acetylcysteine Treatment

Once N-acetylcysteine therapy has been initiated, treatment should continue until appropriate clinical and biochemical stopping criteria are satisfied.

Treatment should not be discontinued solely because the standard 20-, 21-, or 72-hour regimen has been completed.

Some patients require extended antidotal therapy because of persistent paracetamol concentrations or ongoing hepatic injury.

Criteria For Discontinuation

N-acetylcysteine may generally be discontinued when all of the following conditions are satisfied:

Serum Paracetamol Concentration: The concentration has fallen below 10 micrograms/mL, or below the applicable laboratory reporting threshold.

Hepatic Transaminases: AST and ALT are within the patient’s normal range or have decreased substantially, generally by at least 25–50% from their peak concentrations.

Coagulation Status: The international normalized ratio is below 2.0.

Clinical Condition: The patient is clinically stable or improving, without evidence of worsening hepatic failure.

The decision should be individualized and made according to the institutional poisoning protocol, particularly in children with established hepatic injury.

Prolonged Treatment

When treatment criteria have not been satisfied, N-acetylcysteine should be continued with repeated laboratory monitoring.

In patients receiving intravenous treatment, continuation of an appropriate maintenance infusion may be necessary.

Further treatment should be guided by serial serum paracetamol concentrations, hepatic transaminases, coagulation studies, and the child’s overall clinical condition.

Precautions During N-Acetylcysteine Therapy

Intravenous Infusion Reactions

Intravenous N-acetylcysteine may produce non-IgE-mediated hypersensitivity reactions, historically described as anaphylactoid reactions.

Possible manifestations include:

• Flushing.
• Pruritus.
• Urticaria.
• Nausea.
• Bronchospasm.
• Hypotension.

Severe reactions are uncommon but require immediate treatment.

Management Of Infusion Reactions

Depending on the severity of the reaction, management may involve temporarily interrupting or slowing the infusion.

Antihistamines may be administered for cutaneous symptoms.

Bronchodilators may be appropriate when bronchospasm occurs.

Epinephrine is indicated when the clinical presentation is consistent with severe anaphylaxis.

Corticosteroids may occasionally be used as adjunctive therapy.

Once the reaction is controlled, N-acetylcysteine can often be restarted at an appropriate rate under medical supervision.

A previous infusion reaction is not necessarily a contraindication to future N-acetylcysteine treatment when it is clinically required.

Nausea And Vomiting

Both paracetamol poisoning and oral N-acetylcysteine may cause nausea and vomiting.

The unpleasant taste and odor of oral N-acetylcysteine may further reduce tolerance.

Chilling the preparation, using an appropriate flavored diluent, or administering antiemetic medication may improve treatment tolerance.

Nasogastric administration may be considered in selected patients when oral therapy cannot be reliably completed.

Issues For Referral

Children with significant paracetamol poisoning may require consultation with a clinical toxicologist, pediatric hepatologist, or liver transplant specialist.

The urgency of referral depends on the severity and progression of hepatic injury, evidence of impaired liver function, and development of systemic complications.

Elevated Hepatic Transaminases

Marked or progressively increasing AST or ALT concentrations indicate significant hepatocellular injury.

Patients with transaminase concentrations approaching or exceeding 1,000 IU/L, particularly when accompanied by worsening coagulation parameters or other evidence of hepatic dysfunction, should be considered for early consultation with a specialized liver center.

The decision to transfer should not be based on transaminase concentrations alone.

Progressive Hepatic Dysfunction

Referral to a pediatric liver or transplant center is indicated when there is evidence of progressive hepatic injury, worsening coagulopathy, encephalopathy, or multiorgan dysfunction.

Early discussion with a transplant center may be necessary before the development of advanced hepatic failure.

Intentional Overdose

Adolescents presenting after deliberate paracetamol overdose should receive an appropriate mental health assessment.

The evaluation should consider the circumstances surrounding the ingestion, risk of further self-harm, psychological disorders, family support, and the need for ongoing psychiatric care.

Mental health assessment should form part of discharge planning after medical stabilization.

Surgery And Other Procedures

Liver Transplantation

Liver transplantation may be necessary in patients who develop severe paracetamol-induced acute liver failure and are unlikely to recover with medical treatment alone.

Transplantation decisions should be made by a specialist liver transplant team using clinical assessment, laboratory trends, and established prognostic criteria.

King’s College Hospital Criteria

The King’s College criteria are used to identify patients with paracetamol-induced acute liver failure who have a particularly poor prognosis without transplantation.

The criteria include either of the following pathways.

Pathway 1: Severe Metabolic Acidosis

An arterial pH below 7.30 after adequate fluid resuscitation is a major adverse prognostic indicator.

Pathway 2: Combined Organ Dysfunction

All three of the following findings are present:

• Prothrombin time greater than 100 seconds or INR greater than 6.5.
• Serum creatinine greater than approximately 3.4 mg/dL.
• Grade III or IV hepatic encephalopathy.

Some updated assessments also consider persistent elevation of arterial lactate after adequate fluid resuscitation.

These criteria support transplant evaluation but should not replace specialist judgment. In children, additional pediatric-specific clinical considerations are important.

Early transplant-center referral is appropriate when progressive hepatic failure is suspected, even before the full criteria are met.

Admission, Inpatient, And Nursing Considerations

Hospital admission may be necessary for patients requiring N-acetylcysteine therapy, serial biochemical monitoring, or assessment of associated medical and psychological complications.

Admission Criteria

Admission should be considered when:

• N-acetylcysteine therapy is required and cannot be safely completed through an appropriate observation pathway.
• There is evidence of hepatic injury or abnormal liver function.
• Persistent vomiting or other clinical symptoms require supportive treatment.
• Additional drug ingestion is suspected.
• The patient requires psychiatric assessment following intentional overdose.
• There is concern for delayed toxicity, uncertain ingestion timing, or significant comorbid illness.

The level of care should be determined by the severity of poisoning and the child’s clinical stability.

Inpatient Management

Hospitalized children should undergo regular clinical assessment and appropriate laboratory monitoring.

The frequency of investigations depends on the initial findings, treatment regimen, and evidence of ongoing toxicity.

Clinical deterioration should prompt reassessment of the treatment plan and consideration of intensive care or specialist referral.

Discharge Criteria

Discharge may be considered when:

Antidotal Treatment: N-acetylcysteine therapy has been completed or appropriately discontinued according to established stopping criteria.

Hepatic Assessment: There is no evidence of developing or progressive liver injury.

Clinical Stability: The patient is clinically well, able to tolerate appropriate oral intake, and does not require continued inpatient monitoring.

Psychological Assessment: Any indicated mental health evaluation and safety planning have been completed.

Follow-Up: Appropriate medical follow-up and medication safety education have been arranged when necessary.

Ongoing Care

Follow-Up Recommendations

Follow-up depends on the severity of poisoning, the presence of hepatic or renal injury, and the circumstances leading to the overdose.

Children who receive prompt treatment and have no evidence of organ injury may not require prolonged medical surveillance.

Patients with significant biochemical abnormalities or established hepatic injury may require continued monitoring until organ function has normalized or is clearly recovering.

Patient Monitoring

Clinical and laboratory monitoring should focus on identifying progressive liver injury, renal impairment, metabolic disturbances, and treatment-related complications.

Cardiorespiratory Monitoring

Cardiorespiratory monitoring may be appropriate during intravenous N-acetylcysteine therapy, particularly in children with severe poisoning or increased risk of infusion-related reactions.

Monitoring should include observation for hypotension, bronchospasm, respiratory compromise, and other evidence of hypersensitivity.

Liver Function Monitoring

Serial AST, ALT, INR, glucose, and other relevant laboratory measurements should be obtained according to the clinical presentation.

Trends in hepatic transaminases should be interpreted alongside markers of liver function.

Renal Function Monitoring

Serum creatinine, electrolytes, and urine output should be monitored in patients with significant poisoning or suspected renal injury.

Intensive Care Monitoring

Children with fulminant hepatic failure require intensive care management.

Monitoring should include:

• Neurological status and evidence of hepatic encephalopathy.
• Hemodynamic stability.
• Blood glucose.
• Acid-base status and lactate.
• Coagulation parameters.
• Electrolytes.
• Renal function and urine output.

Multidisciplinary care involving pediatric intensive care, clinical toxicology, hepatology, and transplantation specialists may be necessary.

Patient Education

Education Following Repeated Supratherapeutic Dosing

Families of children who develop toxicity from repeated excessive paracetamol administration should receive detailed education regarding safe medication use.

Caregivers should understand how to calculate a weight-based dose, identify the concentration of a liquid formulation, and follow the recommended dosing interval.

They should also be instructed to avoid simultaneous administration of multiple paracetamol-containing products.

A written medication schedule may help reduce administration errors when several caregivers are involved.

Education Following Accidental Ingestion

Families of young children who experience accidental exploratory ingestion should receive home medication safety counseling.

All medications should be kept in secure storage, preferably locked and out of reach of children.

Child-resistant caps should be used, but caregivers should understand that these closures do not make containers completely childproof.

Medicines should not be described as sweets or treats.

Parents should seek immediate medical advice after a suspected overdose rather than waiting for symptoms to appear.

Education For Adolescents

Adolescents should be informed about the risks of taking excessive amounts of paracetamol, including the possibility of serious liver injury even when early symptoms are absent.

When poisoning is intentional, education should be accompanied by appropriate psychological support and safety planning.

Prognosis

The prognosis of paracetamol poisoning depends largely on the amount ingested, timing of treatment, pattern of exposure, and presence of hepatic injury.

Single Acute Ingestion

Among previously healthy children, clinically significant hepatotoxicity is uncommon following a single acute ingestion below approximately 150–200 mg/kg.

However, dose estimates may be inaccurate, and the need for evaluation should be determined by the entire clinical presentation rather than the reported quantity alone.

Prediction Of Hepatotoxicity

Following an acute ingestion with a reliably known time, the Rumack-Matthew nomogram is used to estimate the risk of liver injury and determine whether N-acetylcysteine treatment is indicated.

The nomogram is not applicable to repeated supratherapeutic dosing or exposures with an unknown timing.

Effectiveness Of Early N-Acetylcysteine Treatment

N-acetylcysteine is highly effective in preventing serious paracetamol-induced hepatic injury when administered early.

Treatment initiated within eight hours of an acute overdose provides the greatest protection.

Historical clinical observations have demonstrated prevention of severe hepatotoxicity in more than 99% of appropriately treated patients when therapy begins within this early period, although outcomes vary with the magnitude of exposure and other clinical factors.

Delayed N-Acetylcysteine Treatment

The effectiveness of N-acetylcysteine decreases when initiation is delayed beyond eight hours after ingestion.

Nevertheless, treatment remains beneficial in many late-presenting patients, including those with established liver injury.

N-acetylcysteine should therefore still be administered when clinically indicated, even when the patient presents after the optimal early treatment window.

Repeated Supratherapeutic Dosing

Repeated administration of doses exceeding approximately 75 mg/kg per day deserves careful review, particularly when prolonged or accompanied by risk factors for toxicity.

This amount is not an absolute toxicity threshold, and recommendations for therapeutic maximum daily dosing vary according to age, weight, and clinical context.

Particular caution is warranted in children with:

Febrile Illness: Prolonged illness may be associated with repeated medication administration and altered nutritional intake.

Persistent Vomiting Or Malnutrition: Reduced dietary intake may diminish glutathione reserves and increase susceptibility to hepatocellular injury.

Concurrent Medication Exposure: Anticonvulsants, isoniazid, or other potentially hepatotoxic drugs may complicate risk assessment.

The cumulative dose, duration of treatment, and patient’s clinical condition should be considered together.

Complications

Hepatic Failure

Acute hepatic failure is the most serious complication of paracetamol poisoning.

It results from extensive hepatocellular injury and impaired hepatic synthetic and metabolic function.

Clinical manifestations may include severe coagulopathy, hypoglycemia, metabolic acidosis, encephalopathy, and multiorgan dysfunction.

Some patients may require urgent liver transplantation.

Renal Insufficiency

Acute kidney injury may develop following severe paracetamol poisoning.

Renal dysfunction may occur in association with hepatic failure or, less commonly, as a prominent complication without extensive liver injury.

Patients may develop increasing serum creatinine concentrations, electrolyte abnormalities, and reduced urine output.

Anaphylactoid Reactions During Intravenous N-Acetylcysteine Therapy

Intravenous N-acetylcysteine may occasionally cause significant hypersensitivity-type reactions.

Severe reactions can involve bronchospasm, hypotension, and circulatory compromise.

Anaphylactoid shock is uncommon but requires immediate recognition and emergency treatment.